Why now is the moment to invest in pharmaceutical manufacturing in Nigeria
Four forces have converged for the first time: Nigeria’s dependence on imported medicines has become a national security concern, the multinational import model is visibly collapsing, regulation now actively forces local production, and over a billion euros of development capital is searching for bankable projects. What is missing is not demand, policy or money - it’s the infrastructure and the investable structure to deploy them. That gap is the opportunity.
Author: Theodora Ogharanduku, CEO – Knectiv. Last reviewed: Aug 17, 2026
1. How dependent is Nigeria on imported medicine?
Dangerously, and structurally. Nigeria is the only country with a 100+ million population with such low local pharma manufacturing capacity importing more than 70% of its medicines - a level industry leaders have publicly called a threat to national healthcare stability and economic security (Vanguard). The dependence is deeper still upstream where over 90% of active pharmaceutical ingredients and excipients are sourced externally, leaving the sector exposed to every swing in foreign exchange and every global supply disruption (KPMG).
The market is large but shallow. Nigeria has over 130 pharmaceutical manufacturers, but production is concentrated in simpler, lower value medicines, while complex, higher value products are primarily imported (Health Federation of Nigeria). As of 2026, Emzor Pharmaceutical Industries is the only indigenous API manufacturer leading the move into domestic API production.
This is the demand no marketing has to manufacture.
It is a structural deficit in the fourth largest economy in Africa.
2. Why is the old model breaking down now?
Because the import and distribute model has stopped working for the companies that built it. In August 2023, GlaxoSmithKline ended a 51 year presence in Nigeria, moving to a third party distribution model; Sanofi announced its own exit within months (Nigeria Health Watch) as did Bayer in 2024. The reason was consistent - foreign exchange instability and high operating costs that are unsustainable for businesses reliant on imported inputs (Businessday).
Their departure is not only a warning, it’s a vacuum. Local manufacturers are moving to fill the gap the multinationals left, and the companies that can produce high quality products locally are presented with a market opening that didn’t exist five years ago (Nigeria Health Watch). Every serious player in Nigeria has learnt that importing is now the fragile strategy, and local manufacturing is the resilient one.
3. Is the capital actually there?
Yes, and it is actively looking for projects. The European Union’s Team Europe MAV+ initiative was launched with an initial €1 billion, backed by the European Investment Bank, specifically to de-risk private investment in African pharmaceutical manufacturing, with Nigeria a named focus country (European Commission). Guarantee facilities such as the €750 million Human Development Accelerator now sit behind pharmaceutical and vaccine manufacturing on the continent (Global Gateway Forum). Development finance institutions such as the IFC, AfDB, Proparco and DEG are mandated to deploy into exactly this sector.
Nigeria is also ready to absorb that capital after reaching WHO Maturity Level 3 in 2022 - a benchmark that strengthens the case for manufacturing intended for regional and international markets (MAV+ Nigeria factsheet).
4. So what is actually missing?
Not demand, not policy, not money but investability.
The binding constraints are infrastructure and access to capital, and they compound each other. Industry leaders note that only around 10% of local pharmaceutical companies can access the affordable, long term capital that large scale API manufacturing requires, with unreliable power and poor industrial infrastructure repeatedly named among the primary barriers (National Insight News).
This is the precise gap Genesis Science Park is built to close. By providing power, water, effluent and WHO GMP grade infrastructure as a shared service at park level, it removes the largest and least financeable capital burden from the individual manufacturer - making projects that would otherwise not be bankable, bankable. Demand, policy and capital already exist. What has been missing is somewhere investable to put them.
5. Why a life sciences park, and why now?
Because the window is open and it’s not permanent. The regulatory countdown has started, the capital is mobilised but yet to be deployed, and the multinational retreat has created a supply gap that the first credible, infrastructuren ready manufacturers will capture. A project that starts with validated demand and de-risked infrastructure rather than a land allocation and an announcement is positioned to move while that alignment holds.
→ Express your interest and download the technical prospectus.
For manufacturers that are undertaking a feasibility study, or are operational and expanding.
FAQs
The exits make the case rather than undermine it. GSK, Sanofi and Bayer were import and distribute businesses whose cost base was almost entirely foreign currency denominated, so every devaluation hit them directly. Local manufacturing is the structural hedge against precisely that exposure. The honest caveat - with over 90% of APIs still imported, a fill-and-finish plant does not escape FX entirely, which is exactly why backward integration toward API production and anything that lowers the local cost base - shared infrastructure, reliable power - is where the durable advantage sits. Manufacturing does not remove Nigeria’s risk, it moves you to the side that currency volatility rewards.
Because the mechanism has changed from aspiration to obligation. Earlier targets were policy hopes with no binding consequence; NAFDAC’s 5+5 scheme attaches a dated commercial penalty - localise or lose the right to import - to companies that currently depend on it. Set that against the more than €1 billion of mobilised MAV+ capital and the supply vacuum left by the multinational exits, and the drivers are structural rather than declarative. This is not another target, it’s a deadline with money behind it.
Because the barrier has never been demand, it’s capital and infrastructure. Industry leaders note that only around 10% of local pharmaceutical companies can access the affordable, long term capital that large scale API manufacturing requires, with unreliable power and weak industrial infrastructure named repeatedly as the decisive obstacles. The scarcity of API plants is evidence of that constraint, not evidence that the opportunity is absent - and removing that specific constraint is the entire premise of a shared infrastructure park.
It might, and a thesis resting on a single policy date would be fragile, so this one does not. The 5+5 scheme is an accelerant, not the foundation. The foundation is structural and independent of it - import dependence above 70%, an FX regime that has already forced multinationals out, a supply vacuum, WHO Maturity Level 3 regulatory readiness, and development capital actively searching for projects. A slipped deadline changes the timing of the tailwind, not its direction.
Quality is a design decision, not a national trait. Nigeria reached WHO Maturity Level 3 in 2022, and a facility built to WHO GMP standard from the outset is a fundamentally different proposition from the substandard end of the market. The prevalence of poor quality and falsified product in the region is actually part of the opportunity- this is unmet demand for medicine that can be trusted. The differentiator is building for compliance from day one, which is why WHO GMP is treated as a design premise here, not a later upgrade.